Presto! Proposal eliminates stolen-drug danger

"Drug companies are apparently reluctant to pay the nominal cost of tagging pills and bottles (only about 25 cents a bottle, after an initial investment of $1 million to $2 million)" to implement track-and trace technology, according to a poorly informed New York Times op ed piece. Authors Katherine Eban and J. Aaron Graham, severely misinformed about not just product and implementation costs but also technical challenges, say that the $75 million in drugs taken from an Eli Lilly warehouse last month were not so tagged, making it all the more difficult to find them if they re-enter the legitimate drug supply chain. "The FDA should require that drug makers tag every bottle," they say. "With track-and-trace technology, it is easy to find the packages that are safely in the possession of legitimate wholesalers, hospitals and drugstores." Article

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.